We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Nivolumab
MedXY News
EnglishTag

Nivolumab

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy
Hematology-OncologyNivolumabimmunotherapy

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy

By MedXY|Aug 5, 2026

Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma
Hematology-OncologyBrentuximab vedotin
Ipilimumab

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma

By MedXY|May 4, 2026

In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell tra

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Gastroenterologyablation therapyhepatocellular carcinoma

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

By MedXY|Apr 14, 2026

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial
Clinical Updateshead and neck cancerimmunotherapy

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

By MedXY|Mar 2, 2026

This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238
Dermatologyimmunotherapymelanoma

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238

By MedXY|Feb 5, 2026

The final 9-year analysis of the CheckMate 238 trial confirms that adjuvant nivolumab provides a sustained recurrence-free survival advantage over ipilimumab in patients with resected high-risk melanoma, with 44% of patients remaining recur

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer
newshead and neck cancerneoadjuvant therapy

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer

By MedXY|Jan 11, 2026

This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
Dermatologycutaneous squamous-cell carcinomaIpilimumab

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

By MedXY|Nov 12, 2025

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers
newshepatocellular carcinomaimmunotherapy

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY|Oct 28, 2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety
Dermatologyimmunotherapymelanoma

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY|Oct 25, 2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.

Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy
newsmetforminNivolumab

Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy

By MedXY|Oct 7, 2025

A phase Ib study evaluated the safety, optimal dosing, pharmacokinetics, and preliminary efficacy of metformin with nivolumab in refractory solid tumors, showing good tolerability and promising responses in a subset of patients.

Promising Immunotherapy Combination Shows Durable Responses in Advanced Gynecological Clear Cell Cancers
Clinical UpdatesimmunotherapyIpilimumab

Promising Immunotherapy Combination Shows Durable Responses in Advanced Gynecological Clear Cell Cancers

By MedXY|Oct 4, 2025

A nonrandomized trial reveals that combined nivolumab and ipilimumab treatment achieves a 54% response rate with durable effects in advanced ovarian and endometrial clear cell cancers, addressing critical unmet therapeutic needs.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities